Phase II study of single agent gemcitabine in patients with hormone refractory prostate cancer (HRPC).

被引：0

作者：

Nilsson, S ^{[1
]}

Holmberg, M ^{[1
]}

Ljung, G ^{[1
]}

Pettersson-Skjold, D ^{[1
]}

Blom, R ^{[1
]}

Ullén, A ^{[1
]}

Westberg, R ^{[1
]}

Nilsson, I ^{[1
]}

Lennernas, B ^{[1
]}

机构：

[1] Swedish Prostate Canc Study Grp, Stockholm, Sweden

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4705

引用

页码：432S / 432S

页数：1

共 50 条

[31] Pilot phase II study with docetaxel in combination with curcuminoids in patients with hormone-resistant prostate cancer (HRPC). [J].

Mahammedi, H. ;

Planchat, E. ;

Cure, H. ;

Barthomeuf, C. ;

Bayet-Robert, M. ;

Mouret-Reynier, M. ;

Abrial, C. ;

Thivat, E. ;

Atger, M. ;

Savareux, L. ;

Guy, L. ;

Goyard, J. ;

Chollet, P. J. M. ;

Nabholtz, J. ;

Durando, X. ;

Eymard, J. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)

[32] Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer [J].

Eymard, J.-C. ;

Priou, F. ;

Zannetti, A. ;

Ravaud, A. ;

Lepille, D. ;

Kerbrat, P. ;

Gomez, P. ;

Paule, B. ;

Genet, D. ;

Herait, P. ;

Ecstein-Fraisse, E. ;

Joly, F. .

ANNALS OF ONCOLOGY, 2007, 18 (06) :1064-1070

[33] Actual chemotherapeutical possibilities in hormone-refractory prostate cancer (HRPC) patients [J].

Prezioso, Domenico ;

Galasso, Raffaele ;

Di Martino, Mario ;

Iapicca, Gennaro ;

Annunziata, Emanuele ;

Iacono, Fabrizio .

ANTICANCER RESEARCH, 2007, 27 (02) :1095-1104

[34] Natural history of patients with hormone refractory prostate cancer (HRPC): are they living longer? [J].

Patel, P. ;

Houston, V. ;

Hayne, D. ;

James, N. D. .

BJU INTERNATIONAL, 2010, 105 :4-4

[35] Placebo-controlled, randomized, phase II study of radium-223 in metastatic hormone refractory prostate cancer (HRPC) [J].

Nilsson, S. ;

Franzen, L. ;

Tyrrel, C. ;

Blom, R. ;

Tennvall, J. ;

Lennernas, B. ;

Johannessen, D. C. ;

Sokal, M. ;

Parker, C. ;

Bruland, O. S. .

EJC SUPPLEMENTS, 2007, 5 (04) :295-295

[36] Phase II study of oral capecitabine in patients with hormone-refractory prostate cancer [J].

Spicer, J ;

Plunkett, T ;

Somaiah, N ;

Chan, S ;

Kendall, A ;

Bolunwu, N ;

Pandha, H .

PROSTATE CANCER AND PROSTATIC DISEASES, 2005, 8 (04) :364-368

[37] Dasatinib in patients with hormone-refractory progressive prostate cancer: A phase II study [J].

Yu, E. Y. ;

Wilding, G. ;

Posadas, E. ;

Gross, M. ;

Culine, S. ;

Massard, C. ;

Hudes, G. R. ;

Cheng, S. ;

Paliwal, P. ;

Sternberg, C. N. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)

[38] Phase II study of oral capecitabine in patients with hormone-refractory prostate cancer [J].

J Spicer ;

T Plunkett ;

N Somaiah ;

S Chan ;

A Kendall ;

N Bolunwu ;

H Pandha .

Prostate Cancer and Prostatic Diseases, 2005, 8 :364-368

[39] Predictive modelling in hormone-refractory prostate cancer (HRPC) [J].

Bellmunt, Joaquim ;

Carles, Joan ;

Albanell, Joan .

CLINICAL & TRANSLATIONAL ONCOLOGY, 2009, 11 (02) :82-85

[40] Multicenter phase II trial of S-1 in patients (PTS) with hormone-refractory prostate cancer (HRPC): The S-1 cooperative study group (prostate cancer) [J].

Akaza, Hideyuki ;

Ikemoto, Isao ;

Namiki, Mikio ;

Usami, Michiyuki ;

Kobayashi, Mikio ;

Fujimoto, Hiroyuki ;

Tsukamoto, Taiji ;

Naito, Seiji .

ANNALS OF ONCOLOGY, 2006, 17 :150-150

← 1 2 3 4 5 →